David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity | |
| 8/5/2022 | $2.00 | Buy → Hold | Jefferies | |
| 2/25/2022 | $17.00 → $14.00 | Outperform | Oppenheimer | |
| 2/25/2022 | $16.00 → $9.00 | Outperform | SVB Leerink | |
| 2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald | |
| 11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. | |
| 11/29/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. | |
| 11/2/2021 | $20.00 → $35.00 | Buy | Aegis Capital |
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the CompanyPlans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunityOn track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024
HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecolog
HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024. To access the live conference call by telepho
Clinical data presented at SITC 2024 demonstrated COM701 (anti-PVRIG) mediated anti-tumor activity with durable responses and good tolerability profile in tumors typically not responding to immunotherapy, aligned with previous data presented by the CompanyPlans to initiate, in Q2 2025, an adaptive platform trial in patients with relapsed platinum sensitive ovarian cancer in the maintenance setting, to evaluate single agent COM701 and future combinations representing an unmet need and regulatory and commercial opportunityOn track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024Partner AstraZeneca reported encouraging rilvegostomig data at WCLC and ESMO 2024
HOLON, Israel, Nov. 11, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen management will participate in a fireside chat at the upcoming Stifel 2024 Healthcare Conference in New York City. The fireside chat will take place on Monday, November 18, 2024 at 8:35 am ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event. About CompugenCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predic
HOLON, ISRAEL, Nov. 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that data supporting the anti-tumor activity and safety profile of the triple combination COM701, COM902 and pembrolizumab in advanced heavily pre-treated patients with platinum resistant ovarian cancer (PROC) has been published as an abstract released by the Society for Immunotherapy of Cancer (SITC). This data and additional clinical data will be presented by Oladapo Yeku, M.D., Ph.D., FACP, Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecolog
HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio
HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh
NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned
6-K - COMPUGEN LTD (0001119774) (Filer)
10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00
Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously
SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)